The first participant has been dosed in a clinical trial testing the experimental therapy GLIX1 in people with recurrent or progressive glioblastoma, an aggressive form…
News
May 8 is World Ovarian Cancer Day, a time when advocates around the world raise their voices to increase awareness, support those affected, and…
Gilead said it has completed its $7.8 billion acquisition of Arcellx, a deal the company hopes will allow it to streamline and accelerate the…
The U.S. Food and Drug Administration (FDA) has named Terns Pharmaceuticals’ investigational oral agent TERN-701 a breakthrough therapy for potential use in certain people…
Almost a third of people with advanced pancreatic cancer taking part in an ongoing clinical trial had stable disease following treatment with the experimental…
Advocates across North America are launching a wave of fundraisers and educational campaigns this week as May kicks off Brain Tumor Awareness Month. From high-profile…
The U.S. Food and Drug Administration (FDA) has granted fast track status to a combination of lunresertib and zedoresertib — two therapies in development by…
The Center for Cancer and Blood Disorders (CCBD), a network of community-based oncology practices across Maryland, has launched a program to make CAR…
In adults newly diagnosed with a type of blood cancer called core-binding factor acute myeloid leukemia (CBF-AML), genetic mutations present before treatment do not…
Akeso’s candidate therapy cadonilimab, in combination with chemotherapy, showed encouraging results as a first-line treatment for advanced pancreatic cancer in the Phase 2 COMPASSION-26 study. The…
